This article reports that there is no significant difference in central nervous system relapse rates between intrathecal and systemic administration of methotrexate, casting doubt on the overall efficacy of both approaches.
In this issue of Blood, Orellana-Noia et al report that central nervous system (CNS) relapse rates following either intrathecal (IT) or systemic (IV) adminis-tration of methotrexate (MTX) are not significantly different, shedding doubt on the overall efficacy of both approaches.(1)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
